Higher CD33-SHP-1 interaction in the brain with the CD33 risk allele may result from chronic activation of CD33, maintaining SHP-1 in an active state and facilitating its downstream signaling, ultimately contributing to AD pathology. This evidence concerns the gene CD33 and Alzheimer disease.